An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis

Multicenter REtrospective Study to Evaluate coMpliance to Therapy and Drug survIval of Tocilizumab (TCZ) in patientS With Moderate to Severe actIve rheumatOid Arthritis in routiNe Daily Clinical Practice (REMISSION Study)

This open-label, retrospective, observational study will evaluate the compliance to RoActemra/Actemra (tocilizumab) therapy in patients with moderate to severe rheumatoid arthritis. Six months data will be collected from patients records.

Inclusion Criteria:

• Adult patients, over 18 years of age
• Moderate to severe rheumatoid arthritis
• RoActemra/Actemra treatment must have been initiated 6 months prior to signing the informed consent form

Exclusion Criteria:

• Patients with rheumatic autoimmune disease other than rheumatoid arthritis
• Patients who are not willing to sign the informed consent form
• Patients who participate in interventional trials during the period of this observational study